Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1985-10-15
|
pubmed:abstractText |
The effect of adjuvant CMF (cyclophosphamide, methotrexate and 5-fluorouracil) and tamoxifen (TM) on endocrine function was studied in 120 women with stage I-II operable breast cancer. Sixty patients were premenopausal, of whom 25 were treated with CMF for 9 months, 25 received CMF for 9 months + TM for 2 years, started concurrently, and 10 TM alone for 2 years. In all groups treatment was started within 4 weeks from mastectomy. Sixty patients were postmenopausal and they were all treated with TM alone for 2 years. Plasma levels of estrone + estradiol -17 beta (E1 + E2), follicle stimulating hormone (FSH), luteinizing hormone (LH), prolactin (Prl), and testosterone (T) were determined in all patients before surgery and again at 3-month intervals from initiation of the adjuvant therapy. In ten patients of each treatment group FSH-LH and Prl-TSH release was determined following stimulation with releasing hormones. CMF and CMF + TM therapy resulted in amenorrhea in the majority of premenopausal patients with decrease of E1 + E2 and elevation of FSH-LH plasma concentration to levels of the post-menopausal. In premenopausal women treated with TM a marked increase of E1 + E2 was observed with unaltered FSH-LH plasma concentration. A significant fall of Prl was also present in these patients. In postmenopausal women and premenopausal patients with CMF-induced amenorrhea TM produced a marked fall of FSH-LH and a decrease of Prl plasma level. In no patients was plasma T affected by any of the treatment regimens.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/Hormones,
http://linkedlifedata.com/resource/pubmed/chemical/Methotrexate,
http://linkedlifedata.com/resource/pubmed/chemical/Tamoxifen
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0392-906X
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
4
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
252-5
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:3839720-Adult,
pubmed-meshheading:3839720-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:3839720-Breast Neoplasms,
pubmed-meshheading:3839720-Combined Modality Therapy,
pubmed-meshheading:3839720-Cyclophosphamide,
pubmed-meshheading:3839720-Female,
pubmed-meshheading:3839720-Fluorouracil,
pubmed-meshheading:3839720-Hormones,
pubmed-meshheading:3839720-Humans,
pubmed-meshheading:3839720-Menopause,
pubmed-meshheading:3839720-Methotrexate,
pubmed-meshheading:3839720-Middle Aged,
pubmed-meshheading:3839720-Tamoxifen
|
pubmed:year |
1985
|
pubmed:articleTitle |
Effect of adjuvant tamoxifen and CMF on endocrine function of patients with operable breast cancer.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|